Table 1.

Adverse events (AEs) reported throughout the study period

	Group A(Premedication) (n =10)		Group B(increasing dose) (n =12)
AEs, n (%)	Any grade	Grade≥2	Any grade	Grade≥2
Constitutional symptoms
Pyrexia	5 (50)	1 (10)	3 (25)	2 (17)
Myalgia	4 (40)	0	7 (58)	0
Chills	2 (20)	0	4 (33)	0
Dizziness	2 (20)	0	1 (8)	0
Headache	2 (20)	0	4 (33)	1 (8)
Flushing	2 (20)	0	1 (8)	0
Fatigue	1 (10)	0	1 (8)	0
Other AEs
Activated partial thromboplastin time prolonged	9 (90)	6 (60)	11 (92)	1 (8)
Alanine aminotransferase increased	2 (20)	0	3 (25)	1 (8)
Nausea	3 (30)	0	0	0
Folliculitis	3 (30)	0	0	0
Blurred vision	0	0	2 (17)	0
Eye pain	0	0	1 (8)	0
Vomiting	1 (10)	0	0	0
Injection site extravasation	1 (10)	0	0	0
Injection site reaction	1 (10)	0	1 (8)	0
Contusion	1 (10)	0	0	0
Excoriation	1 (10)	0	0	0
Aspartate aminotransferase increased	1 (10)	0	1 (8)	0
Blood creatine phosphokinase increased	1 (10)	1 (10)	0	0
Gamma-glutamyl transferase increased	1 (10)	0	1 (8)	0
Lymphocyte count decreased	1 (10)	1 (10)	0	0
Decreased appetite	1 (10)	0	0	0
Muscle spasms	0	0	1 (8)	0
Paresthesia	1 (10)	0	0	0
Presyncope	1 (10)	1 (10)	0	0
Haematuria	1 (10)	0	0	0
Dermatitis contact	1 (10)	0	0	0
Hyperhidrosis	1 (10)	0	0	0
Hot flush	1 (10)	0	0	0